Cipher Pharmaceuticals has beaten EPS estimates in three of its last four reported quarters, though its latest result missed. The company reports again after the market closes on November 12.
Cipher Pharmaceuticals Inc. (TSX: CPH) will report third-quarter 2026 results for the period ended September 30. The company will release its results after the market close on Thursday, November 12, and hold a conference call at 8:30 a.m. ET on Friday, November 13.
Recent earnings trend
Cipher Pharmaceuticals Inc
CPH.TO
CPH.TO
Cipher Pharmaceuticals Inc
WealthAwesomeMarket cap
$335.48M
P/E
8.7x
52W high
$20.56
52W low
$12.48
1W change
-0.31%
Beta
0.25
Analyst Price Targets
Based on analyst covering CPH · as of Sep 23, 2026
Wall Street analysts forecast CPH stock price to rise 48.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$19.45
+48.8% Upside
Previously C$19.95 on Sep 17, 2026
Current Price
C$13.07
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CPH's historical volatility
30-Day Vol
21.9%
Annualized
90-Day Vol
46.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$10.93
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$12.31 | C$11.42 – C$13.28 |
| 60 trading days | C$11.60 | C$10.43 – C$12.91 |
| 90 trading days | C$10.93 | C$9.59 – C$12.46 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 2 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-05 | — | 0.2200 | — |
| 2026-06-30 | 2026-08-10 | 0.2100 | 0.2600 | -19.2% |
| 2026-03-31 | 2026-05-07 | 0.3300 | 0.2200 | +50.0% |
| 2025-12-31 | 2026-03-12 | 0.6900 | 0.2100 | +228.6% |
| 2025-09-30 | 2025-11-06 | 0.3000 | 0.1700 | +76.5% |
| 2025-06-30 | 2025-08-07 | 0.3000 | 0.2200 | +36.4% |
For Canadian investors, the main question is whether earnings and revenue meet the modest growth expectations for the quarter. The earnings calendar lists EPS consensus at C$0.22, while a separate trends feed puts it at C$0.32, based on two analysts. That difference is worth checking before you assess the results. Cipher acquires, develops and markets specialty pharmaceutical products in Canada, the U.S. and South America. See the Cipher Pharmaceuticals stock page for company and share information.
Investor takeaway: Cipher beat estimates in three of its last four reported quarters, based on 65 quarters of actual-versus-estimate data. But its latest quarter was a miss, and the two available EPS estimates for September do not match. Check which estimate your data provider uses, and focus on the reported results and management’s comments. Recent beats don’t predict the next quarter.
Two EPS estimates, one report
The earnings calendar lists EPS consensus at C$0.22. The trends feed puts it at C$0.32, based on two analysts, and forecasts revenue of C$18.96 million. The gap is large enough to check which estimate your data provider uses before judging the results.
Cipher’s last four reported quarters showed EPS of C$0.21 versus C$0.26 expected, C$0.33 versus C$0.22, C$0.69 versus C$0.21, and C$0.30 versus C$0.17.
Bull case
The trends feed forecasts EPS of C$0.32, up 8.5% from C$0.30 a year earlier, and revenue of C$18.96 million, up an estimated 4.5%. The EPS consensus has risen from C$0.31 over the past 30 days. Among the two analysts tracked, one raised their estimate and none lowered theirs.
Cipher also posted sizable estimate beats in the March and December 2025 quarters. If the company meets its growth expectations, the results could support the view that its specialty-product portfolio can sustain earnings growth.
Bear case
Cipher’s latest quarter was a miss. For the period ended June 30, it reported EPS of C$0.21 against an estimate of C$0.26, falling short by 19.23%. The September-quarter consensus is based on just two analysts and conflicts with the calendar’s C$0.22 estimate.
Shares last closed at C$13.07, below their 50-day average of C$13.90 and 200-day average of C$15.83. They were down 4.25% over the past month. These figures don’t predict the earnings result, but they help explain why investors may look for signs of steady operating progress.
Analysis
Cipher Pharmaceuticals plans to release its third-quarter 2026 results after the market closes on Thursday, November 12. Its conference call is scheduled for Friday, November 13, at 8:30 a.m. ET.
Cipher acquires specialty products, manages clinical development and regulatory approval, and markets products in Canada, the United States and South America. The report will give investors an update on the business, though the available preview data does not include expectations for individual products.
Analysis
The available EPS estimates differ: the earnings calendar lists C$0.22, while the trends feed gives consensus of C$0.32, with a low estimate of C$0.23 and a high of C$0.41 from two analysts. The feed also forecasts revenue of C$18.96 million, up 4.5% year over year, and EPS growth of 8.5% from C$0.30 a year earlier. Its EPS consensus has risen from C$0.31 over the past 30 days.
Cipher beat estimates in three of its last four reported quarters. EPS was C$0.33 versus C$0.22 for March 2026, C$0.69 versus C$0.21 for December 2025, and C$0.30 versus C$0.17 for September 2025. In June 2026, EPS was C$0.21 against an estimate of C$0.26. The automatically inserted recent-earnings trend table shows the quarter-by-quarter record.
Analysis
The key questions are whether Cipher’s EPS and revenue meet the estimates investors are following, and how management explains the quarter on its November 13 call. The June miss puts execution in focus, while earlier beats show why estimates matter. Neither past results nor consensus guarantees what comes next.
Shares last closed at C$13.07, below their 50-day and 200-day moving averages. You can find analyst targets and the Wealth Awesome statistical forecast on the Cipher analyst ratings page and price prediction page. The model’s 90-day mean is C$10.93, with a 68% range of C$9.59 to C$12.46. This is a model estimate, not investment advice. For more company information, visit the CPH stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
